Literature DB >> 18456508

The PDLIM5 gene and lithium prophylaxis: an association and gene expression analysis in Sardinian patients with bipolar disorder.

Alessio Squassina1, Donatella Congiu, Francesca Manconi, Mirko Manchia, Caterina Chillotti, Simona Lampus, Giovanni Severino, Maria Del Zompo.   

Abstract

A number of studies support the notion that lithium interacts with the protein kinase C (PKC) pathway, an important mediator of several intracellular responses to neurotransmitter signaling. PDLIM5 (PDZ and LIM domain 5; LIM) is an adaptor protein that selectively binds the isozyme PKC(epsilon) to N-type Ca(2+) channels in neurons. We tested for an association between three single nucleotide polymorphisms (SNPs) at the PDLIM5 gene and lithium prophylaxis in a Sardinian sample comprised of 155 bipolar patients treated with lithium. In order to evaluate whether PDLIM5 expression interacts with lithium response, we carried out gene expression analysis in lymphoblastoid cells of 30 bipolar patients. No association was shown between PDLIM5 polymorphisms and lithium response. When PDLIM5 expression was evaluated, no significant differences were detected between Full Responders to lithium (total score>or=7) and other patients (total score<or=6). Our negative findings do not exclude involvement of PDLIM5 in lithium prophylaxis, and further investigation is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18456508     DOI: 10.1016/j.phrs.2008.03.011

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  8 in total

Review 1.  The Role of Pharmacogenomics in Bipolar Disorder: Moving Towards Precision Medicine.

Authors:  Claudia Pisanu; Urs Heilbronner; Alessio Squassina
Journal:  Mol Diagn Ther       Date:  2018-08       Impact factor: 4.074

Review 2.  The role of protein kinase C epsilon in neural signal transduction and neurogenic diseases.

Authors:  Yuan Chen; Qi Tian
Journal:  Front Med       Date:  2011-03-17       Impact factor: 4.592

3.  Pharmacogenomics of mood stabilizers in the treatment of bipolar disorder.

Authors:  Alessio Squassina; Mirko Manchia; Maria Del Zompo
Journal:  Hum Genomics Proteomics       Date:  2010-08-03

4.  Significant association of estrogen receptor binding site variation with bipolar disorder in females.

Authors:  Lisette Graae; Robert Karlsson; Silvia Paddock
Journal:  PLoS One       Date:  2012-02-28       Impact factor: 3.240

5.  Lithium response in bipolar disorder correlates with improved cell viability of patient derived cell lines.

Authors:  Pradip Paul; Shruti Iyer; Ravi Kumar Nadella; Rashmitha Nayak; Anirudh S Chellappa; Sheetal Ambardar; Reeteka Sud; Salil K Sukumaran; Meera Purushottam; Sanjeev Jain; Biju Viswanath
Journal:  Sci Rep       Date:  2020-05-04       Impact factor: 4.379

Review 6.  Genetic influences on response to mood stabilizers in bipolar disorder: current status of knowledge.

Authors:  Janusz K Rybakowski
Journal:  CNS Drugs       Date:  2013-03       Impact factor: 5.749

7.  Peripheral PDLIM5 expression in bipolar disorder and the effect of olanzapine administration.

Authors:  Mohd Aizat Zain; Suffee Nusrat Jahan; Gavin P Reynolds; Nor Zuraida Zainal; Sharmilla Kanagasundram; Zahurin Mohamed
Journal:  BMC Med Genet       Date:  2012-10-02       Impact factor: 2.103

8.  Up-regulation of Bcl-2 expression in cultured human lymphocytes after exposure to low doses of gamma radiation.

Authors:  Hosein Azimian; Mohammad Taghi Bahreyni-Toossi; Abdul Rahim Rezaei; Houshang Rafatpanah; Tayebeh Hamzehloei; Reza Fardid
Journal:  J Med Phys       Date:  2015 Jan-Mar
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.